Opportunities Preloader

Please Wait.....

Report

Global HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031

Market Report I 2023-04-16 I 147 Pages I EMR Inc.

Global HUMIRA (Adalimumab) Drug Market Report and Forecast 2023-2031

Global HUMIRA (Adalimumab) Drug Market Outlook

The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2023-2031, driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment. The market is projected to grow at a CAGR of 1% during the forecast period.

HUMIRA (Adalimumab) Drug Market: Introduction
The global HUMIRA (Adalimumab) drug market is a rapidly growing market that provides treatment for various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by suppressing the immune system and reducing inflammation. It is a widely used drug and is considered as a first-line treatment option for many autoimmune diseases. The increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment are the key drivers of the market.
Expert Market Research has released a comprehensive report on the global HUMIRA (Adalimumab) drug market, which provides an in-depth analysis of the market and its segments. HUMIRA is a widely used drug for the treatment of various autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, psoriasis, and ulcerative colitis. The report covers the market for HUMIRA and provides a detailed analysis of the market size, growth, and trends. The market is highly competitive with several key players involved in the market, focusing on developing new drugs and therapies to strengthen their position in the market.
HUMIRA (Adalimumab) Drug Market- Application and Usage
The global HUMIRA (Adalimumab) drug market is used for the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. HUMIRA is a biologic drug that works by targeting and reducing the activity of a specific protein called tumor necrosis factor-alpha (TNF-alpha) that is involved in causing inflammation in the body. The drug is administered subcutaneously or intravenously, depending on the condition being treated.
Rheumatoid arthritis is one of the primary applications of HUMIRA, and it is widely used as a first-line treatment option for this condition. It is also used for the treatment of psoriasis, which is a chronic skin condition characterized by red, scaly patches on the skin. HUMIRA can provide relief from the symptoms of psoriasis by reducing inflammation in the skin.
In addition to rheumatoid arthritis and psoriasis, HUMIRA is also used for the treatment of Crohn's disease and ulcerative colitis. These are chronic inflammatory bowel diseases that affect the digestive system. HUMIRA can help reduce inflammation in the digestive tract and improve symptoms such as abdominal pain, diarrhea, and rectal bleeding.
HUMIRA (ADALIMUMAB) Drug Market Segmentations
The market can be categorised into indication, type, dosage strength, drug type, distribution channel, and route of administration.
Market Breakup by Indication
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Chronic Plaque Psoriasis
- Crohn's Disease
- Ulcerative Colitis
- Psoriatic Arthritis
- Others

Market Breakup by Type
- Biologics
- Biosimilars
- Adalimumab-ATTO
- Adalimumab-BWWD
- Adalimumab-ADBM
- Adalimumab-ADAZ
- Adalimumab-FKJP
- Adalimumab-AFZB
- Others

Market Breakup by Dosage Strength
- 40MG/0.4ML
- 80MG/0.8ML
- 20MG/0.4ML
- 10MG/0.1ML
- Others

Market Breakup by Drug Type
- Branded
- Generics
- Amjevita
- Hyrimoz
- Hulio
- Others

Market Breakup by Distribution Channels
- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies

Market Breakup by Route of Administration
- Parenteral
- Oral
- Others
Market Breakup by Region
- North America
? United States of America
? Canada
- Europe
? United Kingdom
? Germany
? France
? Italy
? Others
- Asia Pacific
? China
? Japan
? India
? ASEAN
? Australia
? Others
- Latin America
? Brazil
? Argentina
? Mexico
? Others
- Middle East and Africa
? Saudi Arabia
? United Arab Emirates
? Nigeria
? South Africa
? Others


HUMIRA (Adalimumab) drug Market Scenario

The global HUMIRA (Adalimumab) drug market is expected to witness significant growth during the forecast period of 2023-2031. The market is driven by the increasing prevalence of autoimmune diseases and the growing adoption of biologic drugs for their treatment.

North America dominates the HUMIRA drug market, followed by Europe and the Asia Pacific region. The high prevalence of autoimmune diseases and the availability of advanced healthcare infrastructure are driving the growth of the market in North America. Europe is also a significant market for HUMIRA, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.
In addition, the COVID-19 pandemic has also affected the HUMIRA drug market, with disruptions in supply chain and manufacturing activities. However, the market is expected to recover in the post-pandemic period, driven by the increasing demand for effective treatments for autoimmune diseases.
Overall, the global HUMIRA (Adalimumab) drug market is expected to continue its growth trajectory during the forecast period, offering numerous opportunities for key players and investors in the industry.

Key Players in the Global HUMIRA (Adalimumab) drug Market

The report gives an in-depth analysis of the key players involved in the HUMIRA (Adalimumab) drug market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- AbbVie Inc.
- Amgen Inc.
- Fresenius Kabi AG
- Celltrion Healthcare Co Ltd
- Alvotech Ehf.
- Bio-Thera Solutions Ltd.
- Zydus Lifesciences Limited
- Hetero Healthcare Ltd.
- Innovent Biologics, Inc.
- Novartis International AG
- Reliance Life Sciences Pvt. Ltd.
- Samsung C&T Corporation
- Terumo Corp.
- Torrent Pharmaceuticals Ltd.

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 HUMIRA (Adalimumab Drug) Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Investment Scenarios
6.5 Regulatory Framework
6.5.1 Regulatory Overview
6.5.1.1 US FDA
6.5.1.2 EU EMA
6.5.1.3 INDIA CDSCO
6.5.1.4 JAPAN PMDA
6.5.1.5 Others
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Rate
7.3 Awareness and Prevention Gaps
8 Global HUMIRA (Adalimumab Drug) Market
8.1 Global HUMIRA (Adalimumab Drug) Market Overview
8.2 Global HUMIRA (Adalimumab Drug) Market Analysis
8.2.1 Market Overview
8.2.1.1 Global HUMIRA (Adalimumab Drug) Market Historical Value (2016-2022)
8.2.1.2 Global HUMIRA (Adalimumab Drug) Market Forecast Value (2023-2031)
8.3 Global HUMIRA (Adalimumab Drug) Market by Indication
8.3.1 Market Overview
8.3.1.1 Rheumatoid Arthritis
8.3.1.2 Ankylosing Spondylitis
8.3.1.3 Chronic Plaque Psoriasis
8.3.1.4 Crohn's Disease
8.3.1.5 Ulcerative Colitis
8.3.1.6 Psoriatic Arthritis
8.3.1.7 Others
8.4 Global HUMIRA (Adalimumab Drug) Market by Type
8.4.1 Market Overview
8.4.1.1 Biologics
8.4.1.2 Biosimilars
8.4.1.2.1 Adalimumab-ATTO
8.4.1.2.2 Adalimumab-BWWD
8.4.1.2.3 Adalimumab-ADBM
8.4.1.2.4 Adalimumab-ADAZ
8.4.1.2.5 Adalimumab-FKJP
8.4.1.2.6 Adalimumab-AFZB
8.4.1.2.7 Others
8.5 Global HUMIRA (Adalimumab Drug) Market by Dosage Strength
8.5.1 Market Overview
8.5.1.1 40MG/0.4ML
8.5.1.2 80MG/0.8ML
8.5.1.3 20MG/0.4ML
8.5.1.4 10MG/0.1ML
8.5.1.5 Others
8.6 Global HUMIRA (Adalimumab Drug) Market by Drug Type
8.6.1 Market Overview
8.6.1.1 Branded
8.6.1.2 Generics
8.6.1.2.1 Amjevita
8.6.1.2.2 Hyrimoz
8.6.1.2.3 Hulio
8.6.1.2.4 Others
8.7 Global HUMIRA (Adalimumab Drug) Market by Route of Administration
8.7.1 Market Overview
8.7.1.1 Parenteral
8.7.1.2 Oral
8.7.1.3 Others
8.8 Global HUMIRA (Adalimumab Drug) Market by Distribution Channels
8.8.1 Market Overview
8.8.1.1 Hospital Based Pharmacies
8.8.1.2 Online Pharmacies
8.8.1.3 Retail Pharmacies
8.9 Global HUMIRA (Adalimumab Drug) Market by Region
8.9.1 Market Overview
8.9.1.1 North America
8.9.1.2 Europe
8.9.1.3 Asia Pacific
8.9.1.4 Latin America
8.9.1.5 Middle East and Africa
9 North America HUMIRA (Adalimumab Drug) Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe HUMIRA (Adalimumab Drug) Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific HUMIRA (Adalimumab Drug) Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America HUMIRA (Adalimumab Drug) Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa HUMIRA (Adalimumab Drug) Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global HUMIRA (Adalimumab Drug) Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Drug Adoption Parameters
14.4 Porter's Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 AbbVie Inc.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Amgen Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Fresenius Kabi AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Celltrion Healthcare Co Ltd
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Alvotech Ehf.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Bio-Thera Solutions Ltd.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Zydus Lifesciences Limited
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Hetero Healthcare Ltd.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Innovent Biologics, Inc.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Novartis International AG (Sandoz)
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Reliance Life Sciences Pvt. Ltd.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Samsung C&T Corporation
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Terumo Corp.
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Torrent Pharmaceuticals Ltd.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
16 Pricing Models and Strategies (Additional Insight)
16.1 Cost Model
16.1.1 Manufacturing Cost Analysis
16.1.2 Procurement Cost Analysis
16.2 Pricing Strategies
16.2.1 Competitor Pricing Analysis
16.2.2 Key Assessment of Product Attributes
16.2.3 Pricing Benchmark
17 Global HUMIRA (Adalimumab) Drug Market- Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE